Leonardo Bandeira

Leonardo Bandeira

Auto-generated profile, based on publicly available information

Leonardo Bandeira

FBandeira Endocrine Institute, Recife, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in The Lancet
Verified
Journal Article
Closed access
JBJohn P Bilezikian
John P Bilezikian
LBLeonardo Bandeira
Leonardo Bandeira
AKAliya Khan
Aliya Khan
NCNatalie E Cusano
Natalie E Cusano

1 June 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
JFJessica R. Furst
Jessica R. Furst
LBLeonardo C. Bandeira
Leonardo C. Bandeira
WFWen-Wei Fan
Wen-Wei Fan
SASanchita Agarwal
Sanchita Agarwal
KNKyle K. Nishiyama
Kyle K. Nishiyama
MRMishaela R. Rubin
Mishaela R. Rubin
Context: Skeletal deterioration, leading to an increased risk of fracture, is a known complication of type 2 diabetes mellitus (T2D). Yet plausible mechanisms to account for skeletal fragility in T2D have not been clearly established. Objective: The objective of the study was to determine whether bone material properties, as measured by reference point indentation, and advanced glycation endproducts (AGEs), as determined by skin autofluorescence (SAF), are related in patients with T2D. Design: This was a cross-sectional study. Setting: The study was conducted at a tertiary medical center. Patients: Sixteen postmenopausal women with T2D and 19 matched controls participated in the study. Main Outcome Measures: Bone material strength index (BMSi) by in vivo reference point indentation, AGE accumulation by SAF, and circulating bone turnover markers were measured. Results: BMSi was reduced by 9.2% in T2D (P = .02) and was inversely associated with the duration of T2D (r = −0.68, P = .004). Increased SAF was associated with reduced BMSi (r = −0.65, P = .006) and lower bone formation marker procollagen type 1 amino-terminal propeptide (r = −0.63, P = .01) in T2D, whereas no associations were seen in controls. SAF accounted for 26% of the age-adjusted variance in BMSi in T2D (P = .03). Conclusions: Bone material properties are impaired in postmenopausal women with T2D as determined by reference point indentation. The results suggest a role for the accumulation of AGEs to account for inferior BMSi in T2D.

1 May 2019 in Radiology
Verified
Journal Article
Closed access
RYRandy Yeh
Randy Yeh
DTDonovan Tay
Donovan Tay
GTGaia Tabacco
Gaia Tabacco
Laurent DercleLaurent Dercle
Laurent Dercle
JKJennifer H. Kuo
Jennifer H. Kuo
JBJohn P. Bilezikian
John P. Bilezikian
Four-dimensional CT (noncontrast agent enhanced, arterial, and delayed phases) provides superior preoperative localization in patients with primary hyperparathyroidism compared with sestamibi SPECT... Background There currently is no consensus on the optimal localization procedure and imaging protocol for parathyroid adenoma. Parathyroid four-dimensional (4D) CT has emerged as a promising method...

20 November 2016 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
LBLeonardo Bandeira
Leonardo Bandeira
ELE. Michael Lewiecki
E. Michael Lewiecki
JBJohn P. Bilezikian
John P. Bilezikian
Introduction: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway. Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD). Clinical studies with romosozumab have shown dramatic improvements in BMD at the spine and hip. Romosozumab is associated with improvement in bone strength through mechanisms that include increases in bone formation and, different from classical osteoanabolic agents, suppression of bone resorption. Areas covered: Herein, the authors highlight the available data on romosozumab for the treatment of osteoporosis. This includes the latest data on the efficacy, pharmacokinetics and pharmacodynamics as well as safety and tolerability data. Expert opinion: Monthly subcutaneous dosing of romosozumab reduces the risk of vertebral and clinical fractures in women with postmenopausal osteoporosis, with a favorable balance of benefits and risks. Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.

16 November 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
LBLeonardo Bandeira
Leonardo Bandeira
ELE. Michael Lewiecki
E. Michael Lewiecki
Anabolic agents for the treatment of osteoporosis increase bone density, improve bone strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their property of increasing osteoblastic bone formation. Teriparatide and abaloparatide are parathyroid hormone receptor agonists that increase bone remodeling with bone formation increasing more than bone resorption. Romosozumab is a humanized monoclonal antibody to sclerostin that has a “dual effect” of increasing bone formation while decreasing bone resorption. The bone forming effects of anabolic therapy [...] ABSTRACT Anabolic agents for the treatment of osteoporosis increase bone density, improve bone strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their property of increasing osteoblastic bone formation. Teriparatide and abaloparatide are parathyroid hormone receptor agonists that increase bone remodeling with bone formation increasing more than bone resorption. Romosozumab is a humanized monoclonal antibody to sclerostin that has a “dual effect” of increasing bone formation while decreasing bone resorption. The bone forming effects of anabolic therapy

16 November 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
LBLeonardo Bandeira
Leonardo Bandeira
BSBarbara C. Silva
Barbara C. Silva
JBJohn P. Bilezikian
John P. Bilezikian
Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After a first fracture, the risk of a subsequent episode, as well as the risk of death, is higher in the male than in the female population. Despite these facts, only 10% of men with osteoporosis [...] ABSTRACT Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After a first fracture, the risk of a subsequent episode, as well as the risk of death, is higher in the male than in the female population. Despite these facts, only 10% of men with osteoporosis